Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Exact Sciences Cor (NQ: EXAS )

54.66 +1.75 (+3.30%)
Streaming Delayed Price Updated: 11:55 AM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Exact Sciences Cor

< Previous 1 2 Next >
Exact Sciences Unveils Data Showing Promise of Multi-Cancer Early Detection at AACR Special Conference on Liquid Biopsy
From Exact Sciences Corp.
Via Business Wire
Exact Sciences Announces Third-Quarter 2024 Results
From Exact Sciences Corp.
Via Business Wire
Exact Sciences to Participate in November Investor Conference
From Exact Sciences Corp.
Via Business Wire
Exact Sciences Presents Multiple Studies at ACG 2024 Demonstrating Leadership in Noninvasive Colorectal Cancer Screening and Patient Engagement
From Exact Sciences Corp.
Via Business Wire
Exact Sciences Schedules Third Quarter 2024 Earnings Call
From Exact Sciences Corp.
Via Business Wire
FDA Approves Exact Sciences’ Cologuard Plus Test, Setting a New Benchmark in Non-Invasive Colorectal Cancer Screening
From Exact Sciences Corp.
Via Business Wire
Exact Sciences Presents Data Demonstrating Advancement in Blood-based Colorectal Cancer Screening at ESMO 2024
From Exact Sciences Corp.
Via Business Wire
Exact Sciences to Participate in September Investor Conferences
From Exact Sciences Corp.
Via Business Wire
Sector Spotlight: Top 4 Basket of Diagnostic Stocks (EXAS, GH, ILMN, LUDG)
Via AB Newswire
Exposures COVID-19
Exact Sciences Announces First Patient Enrolled in its Multi-Cancer Early Detection (MCED) Falcon Registry Real-World Evidence Study
From Exact Sciences Corp.
Via Business Wire
New Modeling Data Show the Cologuard® Test Has Detected More Than 623,000 Cancers and Precancers Over Past Decade, Saving U.S. Health Care System $22 Billion
From Exact Sciences Corp.
Via Business Wire
Exact Sciences Announces Second-Quarter 2024 Results
From Exact Sciences Corp.
Via Business Wire
Exact Sciences schedules second quarter 2024 earnings call
From Exact Sciences Corp.
Via Business Wire
Myriad Genetics Sees Stock Surge with Hereditary Cancer Tests
Myriad Genetics Inc. (NASDAQ: MYGN) is a leader in genetic testing and precision medicine. The company offers a wide variety of genetic tests including 
Via MarketBeat
Exact Sciences to Participate in June Investor Conferences
From Exact Sciences Corp.
Via Business Wire
Exact Sciences Demonstrates Continued Leadership in Early Cancer Diagnosis and Improved Health Outcomes for Patients with Multiple Data Presentations at ASCO®
From Exact Sciences Corp.
Via Business Wire
Exact Sciences Earns 2024 Great Place To Work® Certification™
From Exact Sciences Corp.
Via Business Wire
Court Ruling Enables Exact Sciences to Proceed with Lawsuit against Geneoscopy
From Exact Sciences Corp.
Via Business Wire
Exact Sciences Announces First-Quarter 2024 Results
From Exact Sciences Corp.
Via Business Wire
Exact Sciences Demonstrates Continued Scientific Advancement in Colorectal Cancer Screening with Multiple Data Presentations at DDW® 2024
From Exact Sciences Corp.
Via Business Wire
Exact Sciences to Participate in May Investor Conference
From Exact Sciences Corp.
Via Business Wire
Exact Sciences Names Aaron Bloomer as New Chief Financial Officer
From Exact Sciences Corp.
Via Business Wire
Exact Sciences Announces Debt Exchange Transaction and Private Placement of Convertible Senior Notes
From Exact Sciences Corp.
Via Business Wire
Exact Sciences to Present Late-Breaking Data from ASCEND-2 Study Validating Its Investigational Multi-Cancer Early Detection Test at AACR Annual Meeting 2024
From Exact Sciences Corp.
Via Business Wire
Exact Sciences Schedules First Quarter 2024 Earnings Call
From Exact Sciences Corp.
Via Business Wire
Exact Sciences to Provide Mayo Clinic Patients with Individualized Cancer Tumor Information to Inform Treatment
From Exact Sciences Corp.
Via Business Wire
Exact Sciences Advances Development of Non-Endoscopic Oncoguard® Esophagus Test to Screen for Esophageal Cancer and Pre-Cancer
From Exact Sciences Corp.
Via Business Wire
Exact Sciences Named 2024 Gallup Exceptional Workplace Award Winner
From Exact Sciences Corp.
Via Business Wire
The New England Journal of Medicine Publishes Cologuard Plus™ Test Results from Pivotal BLUE-C Study
From Exact Sciences Corp.
Via Business Wire
Exact Sciences and Basketball Great Jamal Mashburn Encourage Americans 45+ to Have a Game Plan Against Colon Cancer
From Exact Sciences Corp.
Via Business Wire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.